Ishares Genomics Immunology Etf Performance
| IDNA Etf | USD 21.91 0.01 0.05% |
The etf retains a Market Volatility (i.e., Beta) of 0.43, which attests to possible diversification benefits within a given portfolio. As returns on the market increase, IShares Genomics' returns are expected to increase less than the market. However, during the bear market, the loss of holding IShares Genomics is expected to be smaller as well.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days iShares Genomics Immunology has generated negative risk-adjusted returns adding no value to investors with long positions. Despite latest unfluctuating performance, the Etf's basic indicators remain strong and the current disturbance on Wall Street may also be a sign of long term gains for the ETF investors. ...more
| In Threey Sharp Ratio | -0.88 |
IShares |
IShares Genomics Relative Risk vs. Return Landscape
If you would invest 2,412 in iShares Genomics Immunology on October 22, 2024 and sell it today you would lose (221.00) from holding iShares Genomics Immunology or give up 9.16% of portfolio value over 90 days. iShares Genomics Immunology is currently does not generate positive expected returns and assumes 1.3716% risk (volatility on return distribution) over the 90 days horizon. In different words, 12% of etfs are less volatile than IShares, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
IShares Genomics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for IShares Genomics' investment risk. Standard deviation is the most common way to measure market volatility of etfs, such as iShares Genomics Immunology, and traders can use it to determine the average amount a IShares Genomics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1061
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | IDNA |
Estimated Market Risk
| 1.37 actual daily | 12 88% of assets are more volatile |
Expected Return
| -0.15 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.11 actual daily | 0 Most of other assets perform better |
Based on monthly moving average IShares Genomics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of IShares Genomics by adding IShares Genomics to a well-diversified portfolio.
IShares Genomics Fundamentals Growth
IShares Etf prices reflect investors' perceptions of the future prospects and financial health of IShares Genomics, and IShares Genomics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on IShares Etf performance.
| Total Asset | 170.27 M | |||
About IShares Genomics Performance
By analyzing IShares Genomics' fundamental ratios, stakeholders can gain valuable insights into IShares Genomics' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if IShares Genomics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if IShares Genomics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
The fund generally will invest at least 80 percent of its assets in the component securities of the index and in investments that have economic characteristics that are substantially identical to the component securities of the index and may invest up to 20 percent of its assets in certain futures, options and swap contracts, cash and cash equivalents. Genomics Immunology is traded on NYSEARCA Exchange in the United States.| iShares Genomics Imm generated a negative expected return over the last 90 days | |
| iShares Genomics Imm created five year return of -5.0% | |
| This fund retains 99.56% of its assets under management (AUM) in equities |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in iShares Genomics Immunology. Also, note that the market value of any etf could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the Global Markets Map module to get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes.
The market value of iShares Genomics Imm is measured differently than its book value, which is the value of IShares that is recorded on the company's balance sheet. Investors also form their own opinion of IShares Genomics' value that differs from its market value or its book value, called intrinsic value, which is IShares Genomics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because IShares Genomics' market value can be influenced by many factors that don't directly affect IShares Genomics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between IShares Genomics' value and its price as these two are different measures arrived at by different means. Investors typically determine if IShares Genomics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, IShares Genomics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.